Appendiceal Adenocarcinoma: Mucinous and Nonmucinous Types, Grades, and Treatment
Appendiceal adenocarcinoma is a cancer of the gland cells that line the appendix, with true invasion into the surrounding tissue. It comes in mucinous and nonmucinous (colonic-type) forms and three grades. The 2025 consensus guidelines from the Peritoneal Surface Malignancy (PSM) Consortium recommend a right hemicolectomy for most people, with one exception for well differentiated mucinous tumors confined to the appendix. Chemotherapy, cytoreductive surgery, and HIPEC depend on the grade, the stage, and whether the cancer has spread to the lining of the abdomen.
Appendiceal adenocarcinoma covers several related cancers, and the details on the pathology report change the treatment plan a great deal. Two people can both be told they have adenocarcinoma of the appendix and end up with very different care. We built this page to explain the words on the report and what the 2025 guidelines recommend for each situation.
Everything here follows the 2025 consensus guidelines from the PSM Consortium, led by Dr. Elizabeth Godfrey and colleagues. More than 130 specialists, including surgeons, medical oncologists, pathologists, and patient advocates, voted on each step, and Dr. Michael Foote, who reviewed this page, is one of the authors. Sources are listed at the bottom.
What appendiceal adenocarcinoma is
Adenocarcinoma is cancer that starts in gland cells. Under current World Health Organization (WHO) rules, a tumor of the appendix is called adenocarcinoma only if it shows true infiltrative invasion, meaning cancer cells dig into the tissue around them the way colon cancer does. That separates it from LAMN and HAMN, which push against the wall instead of invading it. In the past, some pathologists called any appendix tumor that caused pseudomyxoma peritonei (PMP) an adenocarcinoma, so older reports can be misleading. Expert pathology review helps sort this out.
The 2025 guidelines estimate that mucinous adenocarcinoma is the most common gland-type cancer of the appendix, at roughly 35 to 40 percent. Colonic or intestinal-type adenocarcinoma makes up about 7 to 27 percent. Goblet cell adenocarcinoma and signet ring cell carcinoma are related but have their own features and their own pages.
Mucinous and nonmucinous adenocarcinoma
- Mucinous adenocarcinoma makes a lot of mucus. By WHO rules, more than half of the tumor is made of extracellular mucin. When it spreads inside the abdomen, it can cause PMP. Our mucinous adenocarcinoma of the appendix page covers it in depth.
- Nonmucinous adenocarcinoma, also called colonic-type or intestinal-type, makes little mucus and looks much like colon cancer under the microscope. When it spreads to the abdomen, it forms solid tumor deposits called peritoneal metastases.
- Undifferentiated carcinoma is rare. Its cells look so abnormal that they show no clear gland pattern, and pathologists count it as high grade.
The three grades of appendiceal adenocarcinoma
The 2025 guidelines use one three-tier grading system. Grade matters more than almost anything else in planning treatment, so it is worth knowing which grade your report gives.
| Grade | Also called | What it means |
|---|---|---|
| Grade 1 (G1) | Well differentiated, low grade | Cells look close to normal and tend to grow slowly. |
| Grade 2 (G2) | Moderately differentiated | In between. Grade 2 is its own category and is not the same as grade 3. |
| Grade 3 (G3) | Poorly differentiated, high grade | Cells look very abnormal and tend to grow and spread faster. Signet ring cells place a tumor in grade 3. |
When appendiceal adenocarcinoma spreads to the abdomen, the disease there gets its own grade. The guidelines use PMP grade 1, 2, and 3, matching older terms: grade 1 is the same as low-grade mucinous carcinoma peritonei or DPAM, grade 2 matches high-grade mucinous carcinoma peritonei or PMCA, and grade 3 is high-grade disease with signet ring cells. The grade in the abdomen can differ from the grade in the appendix. When it is higher, the disease in the abdomen guides treatment. Our post on why your appendix and your PMP can have different grades explains this.
Staging
Appendiceal adenocarcinoma uses TNM staging much like colon cancer. The T category describes how deep the tumor goes, N describes lymph nodes, and M describes spread. In the M category, M1a means mucin without tumor cells inside the abdomen, M1b means tumor cells inside the abdomen, and M1c means spread beyond the abdominal lining, such as to the liver or lungs. The types of appendix cancer page lists every T and N category.
Tests after an appendiceal adenocarcinoma diagnosis
The 2025 guidelines recommend this workup:
- A detailed history and physical exam.
- Blood tumor markers: CEA, CA-125, and CA 19-9, with CRP considered.
- CT or MRI imaging, if not already done.
- A colonoscopy to look for a separate growth in the colon.
- Review of the tissue by an expert pathologist and discussion at a multidisciplinary tumor board.
- Comprehensive tumor profiling (genomic testing of the tumor) to look for possible drug targets, and germline testing for inherited cancer risk considered alongside family history.
- A circulating tumor DNA (ctDNA) blood test may be considered, particularly for high-grade or signet ring cell tumors, though evidence in appendix cancer is limited.
Treatment when the cancer has not spread to the abdomen
Surgery
The guidelines recommend a right hemicolectomy for most people with appendiceal adenocarcinoma. This removes the right side of the colon with its lymph nodes, aiming for at least 12 nodes as in colon cancer. The one exception is a well differentiated (grade 1) mucinous adenocarcinoma that is completely confined to the appendix with clean margins and no sign of spread. In that case, lymph nodes are rarely involved, and a hemicolectomy may not add benefit.
Chemotherapy after surgery
- Stage III (cancer in at least one lymph node), or stage II with high-risk features: the guidelines say to consider chemotherapy after surgery, usually FOLFOX or a stronger three-drug regimen such as FOLFOXIRI or FOLFIRINOX, which has more side effects. Treatment usually lasts 3 to 6 months, with a goal of 6.
- Stage I or II without high-risk features: surveillance, because there is not enough evidence that chemotherapy helps.
- Low-grade or well differentiated adenocarcinoma without spread: no evidence currently supports chemotherapy.
The high-risk features confirmed in appendix studies are lymph node involvement, signet ring cells, and less differentiated or nonmucinous histology. Other features, such as a T4 tumor, perforation, or too few lymph nodes examined, come from colon cancer studies and have not been confirmed in appendix cancer. The guidelines do not recommend chemotherapy before surgery when the cancer has not spread. Our post on chemotherapy after surgery for localized appendix cancer covers a recent MD Anderson study on this question.
Treatment when appendiceal adenocarcinoma has spread to the abdomen
About 40 to 50 percent of appendix tumors have already spread when they are found, most often to the peritoneum, the lining of the abdomen. Part 2 of the 2025 guidelines organizes treatment by the grade of the disease in the abdomen.
Grade 1 mucinous disease in the abdomen
When complete removal of the disease looks possible, the guidelines recommend cytoreductive surgery (CRS) with intraperitoneal chemotherapy, such as heated chemotherapy (HIPEC), including a right hemicolectomy for adenocarcinoma. A more limited bowel operation may be considered for well differentiated mucinous tumors if a hemicolectomy is not needed to remove everything. Chemotherapy through the vein has generally not been shown to help grade 1 disease, but it is recommended if the tumor in the appendix has high-risk or high-grade features. Even when complete removal does not look possible, partial cytoreduction with intraperitoneal chemotherapy may be considered.
Grade 2 or grade 3 mucinous disease in the abdomen
The guidelines recommend both CRS and chemotherapy through the vein. Most experts prefer to give chemotherapy first, to see how the cancer responds, and then plan surgery. If complete removal does not look possible at the start, chemotherapy comes first and the plan is reassessed. Chemotherapy usually totals about 6 months, finished after surgery if not completed before.
Nonmucinous disease in the abdomen
For nonmucinous adenocarcinoma that has spread to the abdomen, the guidelines recommend chemotherapy first, then a response check before any surgery. Going straight to CRS is not preferred. If someone does have surgery first, they should get a full course of chemotherapy afterward.
When surgery cannot remove all the disease
For higher-grade mucinous or any nonmucinous disease, if complete removal still does not look possible after chemotherapy, the guidelines advise against CRS as a definitive treatment. Options then include more chemotherapy, clinical trials, and supportive care. Debulking surgery may still help some people with symptoms, but it is not curative. The medical centers and providers page lists centers with experience in this surgery.
Surveillance after appendiceal adenocarcinoma
Every follow-up visit includes a history and physical exam, CT or MRI of the chest, abdomen, and pelvis, and a CEA blood test plus any other marker that was ever high. The 2025 guidelines set different schedules:
- No spread to the abdomen: every 3 to 6 months for 2 to 4 years, then once a year until 5 to 10 years.
- After treatment for grade 1 disease in the abdomen: every 6 months for 2 years, then yearly for 2 years, then every 2 years until 5 to 10 years.
- After treatment for grade 2, grade 3, or nonmucinous disease in the abdomen: every 3 months for 2 years, then every 6 months for 2 years, then yearly until 5 to 10 years.
For grade 2, grade 3, and nonmucinous disease, the guidelines suggest considering ctDNA testing every 3 months for the first year. A second-look laparoscopy may be considered when there is concern about early spread that scans can miss.
The genetics of appendiceal adenocarcinoma
The 2025 guidelines list the most common gene changes in appendix cancer as KRAS (more than 70 percent), GNAS (50 to 70 percent), TP53 (up to 40 percent), and APC (up to 20 percent). This pattern differs from colon cancer, which is one reason colon cancer treatments do not always work the same way here. Tumors driven mainly by GNAS are less likely to respond to chemotherapy, while TP53 changes are linked with higher-grade disease. MSI-high or mismatch repair deficient tumors are uncommon, at about 6 percent, but they may respond to immunotherapy.
The guidelines recommend genomic testing of the tumor, preferably on tissue, for everyone whose cancer has spread. They note that bevacizumab, a drug that blocks blood vessel growth, may be considered in many settings, and that a small trial of an immunotherapy and bevacizumab combination showed promising disease control in low-grade mucinous adenocarcinoma that could not be removed. Studies like these are small. Pooling data from many patients is how the field learns which treatments help which tumors, and it is why the Appendicure registry exists.
Add your adenocarcinoma data to the registry
The Appendicure Patient-Led Global Appendix Cancer Registry collects pathology, genomic, and molecular data from people with every appendiceal cancer type, including adenocarcinoma. It is IRB-reviewed, free, and open worldwide. Please use the form for where you live.
Already enrolled? Add new reports or correct your record.
Frequently asked questions about appendiceal adenocarcinoma
What is the difference between mucinous and nonmucinous appendiceal adenocarcinoma?
Mucinous appendiceal adenocarcinoma is mostly made of mucus and usually causes pseudomyxoma peritonei if it spreads. Nonmucinous, or colonic-type, adenocarcinoma makes little mucus, looks like colon cancer, and forms solid tumor deposits if it spreads to the abdomen.
Do I need a right hemicolectomy for appendiceal adenocarcinoma?
For most people, yes. The 2025 PSM Consortium guidelines recommend a right hemicolectomy with lymph node removal, except for a well differentiated (grade 1) mucinous adenocarcinoma that is completely confined to the appendix with clean margins.
Is grade 2 appendiceal adenocarcinoma high grade?
No. The 2025 guidelines use three grades. Grade 2, or moderately differentiated, is its own category, separate from grade 3, which is high grade.
Do I need chemotherapy for appendiceal adenocarcinoma?
It depends on grade and stage. Chemotherapy is considered after surgery for stage III or high-risk stage II disease, recommended before or around cytoreductive surgery for grade 2 or 3 disease in the abdomen, and generally not used for grade 1 disease without high-risk features.
Is HIPEC used for appendiceal adenocarcinoma?
When the cancer has spread to the abdomen and can be completely removed, the guidelines recommend cytoreductive surgery, often with intraperitoneal chemotherapy such as HIPEC. The best drug and method are still debated.
How long is follow-up after appendiceal adenocarcinoma?
Follow-up lasts 5 to 10 years. Scans and blood tests are every 3 to 6 months at first, with the exact schedule depending on whether and how the cancer spread to the abdomen.
Related reading
Sources
- Godfrey EL, Mahoney F, Bansal VV, et al. Consensus guideline for the management of patients with appendiceal tumors, part 1: Appendiceal tumors without peritoneal involvement. Cancer. 2025;131(13):e35867. doi.org/10.1002/cncr.35867
- Godfrey EL, Mahoney F, Bansal VV, et al. Consensus guideline for the management of patients with appendiceal tumors, part 2: Appendiceal tumors with peritoneal involvement. Cancer. 2025;131(13):e35874. doi.org/10.1002/cncr.35874
- Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182-188. doi.org/10.1111/his.13975
- Carr NJ, Cecil TD, Mohamed F, et al. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the PSOGI modified Delphi process. Am J Surg Pathol. 2016;40(1):14-26. doi.org/10.1097/PAS.0000000000000535
Medically reviewed by Michael Foote, MD, Medical Oncologist & Physician-Scientist, Memorial Sloan Kettering. This page was written with AI assistance. It is for education and does not replace advice from your own care team. Last updated November 2026.
